Thirty patients receiving haemodialysis, including two who had undergone bilateral nephrectomy, showed significant increases (p <0001) in packed cell volume, haemoglobin concentration, and reticulocyte count during an episode of viral or toxic liver cytolysis. In 19 cases the episode lasted a mean of 5 0±SD 2-9 months and was accompanied by improved haematological values for a mean of 12 0+6-0 weeks. Of the remaining patients, in whom the episode lasted a mean of 8 0±3-5 months (p <0 02), seven showed continued improvement a mean of 30 0+16-0 weeks after cytolysis. In eight patients in this group there was an apparent correlation between persistently increased haemoglobin concentrations and biopsy evidence of chronic hepatitis.
Introduction
Anaemia in chronic renal failure is associated with a reduced life span of erythrocytes and diminished erythropoiesis. 1 The impaired red-cell production probably has a multifactorial aetiology, including uraemic toxicity2 and reduced production of renal erythropoietin. The lack of renal erythropoietin may these patients to see whether injured or regenerating liver has a vicarious erythropoietic role in uraemia.
Patients and methods
We studied 30 patients (20 men and 10 women) retrospectively. They had been receiving haemodialysis for 12-78 months, and two had undergone bilateral nephrectomy two years and one year respectively after beginning haemodialysis. All suffered an episode of liver cytolysis (mean maximum serum alanine transaminase (serum ALT; SGPT) activity 311.5 ± SD 221-8 IU/l (normal 6<40 0 IU/1)), which had lasted for a mean of 6-0 SD 3 4 months. Nineteen of the episodes had resulted from a viral hepatitis (caused by hepatitis B surface antigen (HBsAg) in 18 cases and cytomegalovirus (CMV) in one); nine from drug toxicity (allopurinol in four cases, fluoxymesterone in two, methyldopa in two, and aspirin and paracetamol in one); and two were unexplained. Of the nine episodes caused by drug toxicity, five occurred in carriers of HBsAg. In no case was liver cytolysis accompanied or followed by impaired liver function.
In each patient the predialysis packed cell volume, haemoglobin concentration, mean cell volume, reticulocyte count, and serum iron concentration were determined at least monthly before, during, and after the episode of cytolysis. Out of 11 patients with a protracted episode, eight underwent liver biopsy (Menghini) repeated after an interval of one year. All patients were taking folic acid supplements and received intravenous iron at regular intervals. The mode of dialysis continued unchanged during the observation period. Before the episode of cytolysis four patients, including the two anephric patients and one with chronic respiratory failure, required regular blood transfusions because of poor tolerance of haemoglobin concentrations below 6-0 g/dl. The 30 patients fell into two distinct groups-namely, 19 patients (group 1) in whom the duration of liver cytolysis (mean 5 0±SD 2 9 months) was compatible with "acute" hepatitis, and 11 patients (group 2) in whom the duration (mean 8 0±3 5 months) was compatible with "chronic" hepatitis.5 This difference was significant (p < 0 02).
When all patients were considered the episode of liver cytolysis was accompanied by significant increases (p < 0.001) in mean packed cell volume, haemoglobin concdntration, and reticulocyte count (table) . The mean cell volume, however, was unchanged. Figure 1 shows the changes in haemoglobin concentrations and circulating reticulocytes in groups 1 and 2 considered separately. With the reduction in anaemia the four patients who had been intolerant of haemoglobin concentrations below 6-0 g/dl no longer required blood transfusions (fig 2) . Of these, three had been receiving [1] [2] [3] 26 patients the amelioration of anaemia began 11-0 SD 5-0 weeks after the initial rise in serum ALT activity. All patients were greatly improved in their general condition, wellbeing, and tolerance of exertion during the episode.
In group 1 the improvement in anaemia lasted for a mean of 12 0-SD 6 0 weeks. The mean reticulocyte count then decreased (p <0001) and the haemoglobin concentration and packed cell volume returned to precytolysis values (fig 1) . Of the 11 patients in group 2, seven continued to have an improved reticulocyte count, haemoglobin concentration, and packed cell volume a mean of 30 0 -16 0 weeks after cytolysis, though in the other four these values had diminished. Needle biopsies in eight patients in this group showed chronic persistent hepatitis in five, chronic active hepatitis in two, and cirrhosis in one.
The two anephric patients were in group 2. In one (case 4; fig 2) cytolysis and then cholestasis were still present 78 weeks after beginning and 52 weeks after stopping treatment with paracetamol 
During this period the anaemia was improved. Fifteen weeks after the disappearance of cytolysis she became HBsAg-negative, and subsequently her packed cell volume fell to precytolysis values.
Discussion
The anaemia of chronic renal failure results from the inability of erythropoiesis to compete with blood losses and accelerated red-cell destruction.' Probably many factors contribute to the impaired production of red cells, including uraemic toxicity2 and inadequate secretion of erythropoietin.3 That lack of renal erythropoietin may be a dominant factor, however, was strongly suggested by evidence that the anaemia is more severe in anephric subjects than in other patients receiving haemodialysis.4
In our series of uraemic patients an episode of viral or toxic liver damage was accompanied by improved erythropoiesis. The possibility that this resulted from a diminution of hepatic inhibitors of residual renal erythropoietin, however, is ruled out because the two anephric patients also showed improvement, with increased reticulocyte counts and a sustained reduction in their anaemia. Kolk-Vegter et a16 and Coleman et all reported similar observations in 11 anephric patients.
We postulate that in our patients the injured liver became a source of extrarenal erythropoietin. The delayed onset of reticulocytosis after the beginning of cytolysis suggests that hepatocyte regeneration rather that hepatocyte destruction was the stage when this erythropoietin secretion occurred. Possibly regenerating hepatocytes recover some of their function observed in the fetus.8
That the liver may produce erythropoietin is supported clinically and experimentally. Fried9 and Naughton et al'l found that regenerating hepatocytes played an important part 18, in the production of extrarenal erythropoietin in rats, and Cannon and Pennington" and Gordon et al"2 reported erythropoietin secretion by primary liver tumours in man. Possibly the erythrocytosis of acute viral hepatitis"3 is also mediated by erythropoietin, though that remains to be investigated.
Other workers have noted increased haemoglobin concentrations in uraemic patients with HBsAg hepatitis.6 7 Our findings show that drug-induced liver cytolysis also increases red-cell production in uraemia. We have documented elsewhere the unsuspected number of hepatotoxic drugs that are prescribed in uraemia,14 which may explain the reportedly beneficial effects of androgens15 16 and intravenous iron '7 on the anaemia of chronic renal failure.
Interestingly our patients in group 2 showed an apparent correlation between persistently raised haemoglobin concentrations and biopsy evidence of chronic hepatitis.'4 If this is confirmed a sustained improvement in anaemia after liver cytolysis could be used as additional evidence in tests for persisting liver damage.
Finally, possibly some forms of liver extracts could be utilised for treating renal anaemia.
Requests for reprints should be sent to Dr Alain Meyrier. Summary and conclusions Daytime somnolence or excessive snoring, or both, occurred in five out of 11 patients with acromegaly. All five had episodes of sleep apnoea, and three had the sleep apnoea syndrome. Growth hormone concentrations were higher (p <0 025) in these patients than in the six patients without these symptoms. One patient with daytime somnolence and one asymptomatic patient had flow loop evidence of upper airways obstruction. Two of the patients with the sleep apnoea syndrome had cardiomegaly.
Sleep apnoea appears to be common and clinically 
Introduction
Upper airways obstruction may be a complication of acromegaly owing to enlargement of the soft tissues of thc oropharynx.1 Upper airways obstruction from many causes may be associated with daytime somnolence and repeated episodes of sleep apnoea.' Sleep apnoea 3 4and daytime somnolence5 in acromegaly have been reported. The daytime somnolence may remit rapidly after the acromegaly has been treated,5 suggesting that it is not solely due to anatomical abnormalities of upper airways. We have studied 11 patients with acromegaly to determine the relation between upper airways obstruction, daytime somnolence, and sleep apnoea and the prevalence of these features.
Patients and methods
We studied 11 patients (five men and six women); table I gives clinical details. Acromegaly had been confirmed in all cases by the finding of raised growth hormone concentrations that did not fall after a glucose load. Two patients (cases 8 and 9) were newly diagnosed
